Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?

被引：4
|
作者：
Takahari, Daisuke [1 ]
Chin, Keisho [1 ]
Yamaguchi, Kensei [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Tokyo, Japan
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 24期
关键词：
first-line chemotherapy; gastric cancer; pembrolizumab monotherapy; TAS-118 plus oxaliplatin; SOL; DOUBLE-BLIND; PHASE-III; CISPLATIN; NIVOLUMAB; S-1;
D O I：
10.2217/fon-2020-0421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1797 / 1799
页数：3
相关论文
共 50 条
  • [41] GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-assessment for Initially HER2-Negative Advanced Gastric Cancer Patients after Progression on First-Line Treatment
    Hyung, Jaewon
    Kim, Hyung-Don
    Ryu, Min-Hee
    Park, Young Soo
    Moon, Meesun
    Kang, Yoon-Koo
    CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 199 - 207
  • [42] Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer
    Lu, Xunxi
    Gou, Zongchao
    Chen, Hong
    Li, Li
    Chen, Fei
    Bao, Chunjuan
    Bu, Hong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08) : 1 - 13
  • [43] Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab
    Pizzuti, Laura
    Sergi, Domenico
    Sperduti, Isabella
    Di Lauro, Luigi
    Mazzotta, Marco
    Botti, Claudio
    Izzo, Fiorentino
    Marchetti, Luca
    Tomao, Silverio
    Marchetti, Paolo
    Natoli, Clara
    Grassadonia, Antonino
    Gamucci, Teresa
    Mentuccia, Lucia
    Magnolfi, Emanuela
    Vaccaro, Angela
    Cassano, Alessandra
    Rossi, Ernesto
    Botticelli, Andrea
    Sini, Valentina
    Sarobba, Maria G.
    Fabbri, Maria Agnese
    Moscetti, Luca
    Astone, Antonio
    Michelotti, Andrea
    De Angelis, Claudia
    Bertolini, Ilaria
    Angelini, Francesco
    Ciliberto, Gennaro
    Maugeri-Sacca, Marcello
    Giordano, Antonio
    Barba, Maddalena
    Vici, Patrizia
    CANCER BIOLOGY & THERAPY, 2018, 19 (04) : 328 - 334
  • [44] Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer
    Bertucci, Francois
    De Nonneville, Alexandre
    Finetti, Pascal
    Mamessier, Emilie
    CANCER COMMUNICATIONS, 2023, 43 (08) : 943 - 946
  • [45] Authors' reply to 'RE: A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group'
    Nishina, Tomohiro
    Boku, Narikazu
    Kurokawa, Yukinori
    Sasaki, Keita
    Machida, Ryunosuke
    Yoshikawa, Takaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (01) : 89 - 90
  • [46] Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
    Shingaki, Sumito
    Kogawa, Takahiro
    Shimokawa, Mototsugu
    Haranol, Kenichi
    Naito, Yoichi
    Kusuharal, Shota
    Fujimoto, Yumi
    Matsubaral, Nobuaki
    Hosono, Ako
    Mukail, Hirofumi
    Onishi, Tatsuya
    Hojo, Takashi
    Mukohara, Toru
    JOURNAL OF CANCER, 2020, 11 (14): : 4099 - 4105
  • [47] Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan
    Kashiwa, Munenobu
    Matsushita, Ryo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (07) : 895 - 903
  • [48] Blood alkaline phosphatase predicts prognosis of patients with advanced HER2-negative gastric cancer receiving immunotherapy
    Hu, Jianli
    Yang, Shengli
    Wang, Jing
    Zhang, Qiuyue
    Zhao, Lei
    Zhang, Dejun
    Yu, Dandan
    Jin, Min
    Ma, Hong
    Liu, Hongli
    Xue, Jun
    Zhang, Tao
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
  • [49] Plasma ESR1 mutations and outcome to first-line chemotherapy with bevacizumab and paclitaxel in patients with advanced ER-positive/HER2-negative breast cancer
    Bos, M. K.
    Lam, S. W.
    Helmijr, J. C. A.
    Beaufort, C. M.
    Jager, A.
    Martens, J. W. M.
    Boven, E.
    Jansen, M. P. H. M.
    Sleijfer, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S32 - S33
  • [50] Trastuzumab and taxane chemotherapy in the first-line in MBC patients with a HER2-negative primary tumor and HER2-positive circulating tumor cells: a phase II trial
    Verschoor, Noortje
    Bos, Manouk
    de Kruijff, Inge
    Van, Ngoc M.
    Kraan, Jaco
    Drooger, Jan
    Zuetenhorst, Johanna
    Wilting, Saskia M.
    Sleijfer, Stefan
    Jager, Agnes
    Martens, John Wm
    CANCER RESEARCH, 2024, 84 (09)
12345